{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:52:23Z","timestamp":1788922343896,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Novo Nordisk A\/S"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s11095-024-03771-6","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T17:02:11Z","timestamp":1728406931000},"page":"1991-2014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs"],"prefix":"10.1007","volume":"41","author":[{"given":"Morten","family":"Hach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorthe Kot","family":"Engelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Mysling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper Emil","family":"Mogensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Schelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim F.","family":"Haselmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper","family":"Lamberth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Kvistgaard","family":"Vilhelmsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Malmstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Bonde","family":"H\u00f8jlys-Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Secher","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Borch-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus Worm","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Marker Thams","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Regitze","family":"Kesting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei-Mircea","family":"Catarig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e J.","family":"Asgreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0551-8936","authenticated-orcid":false,"given":"Arne","family":"Staby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"3771_CR1","unstructured":"US Food & Drug Administration. ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/andas-certain-highly-purified-synthetic-peptide-drug-products-refer-listed-drugs-rdna-origin. Accessed 20 May 2024."},{"key":"3771_CR2","unstructured":"US Food & Drug Administration. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations. 2019. https:\/\/www.fda.gov\/media\/125484\/download. Accessed 20 May 2024."},{"key":"3771_CR3","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 20 May 2024."},{"key":"3771_CR4","unstructured":"European Medicines Agency. Guideline on the development and manufacture of synthetic peptides. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-development-and-manufacture-synthetic-peptides_en.pdf. Accessed 20 May 2024."},{"key":"3771_CR5","unstructured":"Novo Nordisk. Wegovy\u00ae prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215256s000lbl.pdf. Accessed 10 June 2024."},{"key":"3771_CR6","unstructured":"Novo Nordisk. Wegovy\u00ae summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/wegovy-epar-product-information_en.pdf. Accessed 23 May 2024."},{"key":"3771_CR7","unstructured":"Novo Nordisk. Ozempic\u00ae summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ozempic-epar-product-information_en.pdf. Accessed 20 May 2024."},{"key":"3771_CR8","unstructured":"Novo Nordisk. Ozempic\u00ae prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209637s020s021lbl.pdf. Accessed 23 May 2024."},{"key":"3771_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/asj\/sjad211","volume":"44","author":"SH Han","year":"2023","unstructured":"Han SH, Safeek R, Ockerman K, Trieu N, Mars P, Klenke A, et al. Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a Google Trends analysis. Aesthet Surg J. 2023;44:60\u20137.","journal-title":"Aesthet Surg J"},{"key":"3771_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/ajhp\/zxad086","volume":"80","author":"EM Tichy","year":"2023","unstructured":"Tichy EM, Hoffman JM, Tadrous M, Rim MH, Suda KJ, Cuellar S, et al. National trends in prescription drug expenditures and projections for 2023. Am J Health Syst Pharm. 2023;80:899\u2013913.","journal-title":"Am J Health Syst Pharm"},{"key":"3771_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, D\u2019Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72\u2013130.","journal-title":"Mol Metab"},{"key":"3771_CR12","unstructured":"Novo Nordisk. Rybelsus\u00ae prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/213051s000lbl.pdf. Accessed 10 June 2024."},{"key":"3771_CR13","unstructured":"Novo Nordisk. Rybelsus\u00ae summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rybelsus-epar-product-information_en.pdf. Accessed 23 May 2024."},{"key":"3771_CR14","unstructured":"Novo Nordisk. Victoza\u00ae summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/victoza. Accessed 20 May 2024."},{"key":"3771_CR15","unstructured":"Novo Nordisk. Victoza\u00ae prescribing information. 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022341lbl.pdf. Accessed 10 June 2024."},{"key":"3771_CR16","unstructured":"Novo Nordisk. Saxenda\u00ae summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/saxenda-epar-product-information_en.pdf. Accessed 3 June 2024."},{"key":"3771_CR17","unstructured":"Novo Nordisk. Saxenda\u00ae prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206321s007lbl.pdf. Accessed 10 June 2024."},{"key":"3771_CR18","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","volume":"44","author":"CF Deacon","year":"1995","unstructured":"Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44:1126\u201331.","journal-title":"Diabetes"},{"key":"3771_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3771_CR20","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau J, Bloch P, Sch\u00e4ffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58:7370\u201380.","journal-title":"J Med Chem"},{"key":"3771_CR21","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s40262-015-0343-6","volume":"55","author":"LV Jacobsen","year":"2016","unstructured":"Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2016;55:657\u201372.","journal-title":"Clin Pharmacokinet"},{"key":"3771_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11095-020-02817-9","volume":"37","author":"A Staby","year":"2020","unstructured":"Staby A, Steensgaard DB, Haselmann KF, Marino JS, Bartholdy C, Videb\u00e6k N, et al. Influence of production process and scale on quality of polypeptide drugs: a case study on GLP-1 analogs. Pharm Res. 2020;37:120.","journal-title":"Pharm Res"},{"key":"3771_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12934-021-01650-y","volume":"20","author":"A Tippelt","year":"2021","unstructured":"Tippelt A, Nett M. Saccharomyces cerevisiae as host for the recombinant production of polyketides and nonribosomal peptides. Microb Cell Fact. 2021;20:161.","journal-title":"Microb Cell Fact"},{"key":"3771_CR24","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","volume":"23","author":"VR Aroda","year":"2022","unstructured":"Aroda VR, Blonde L, Pratley RE. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev Endocr Metab Disord. 2022;23:979\u201394.","journal-title":"Rev Endocr Metab Disord"},{"key":"3771_CR25","doi-asserted-by":"crossref","unstructured":"Zapadka KL, Becher FJ, Gomes Dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017;7:20170030.","DOI":"10.1098\/rsfs.2017.0030"},{"key":"3771_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s13181-020-00814-3","volume":"17","author":"CJ Watson","year":"2021","unstructured":"Watson CJ, Whitledge JD, Siani AM, Burns MM. Pharmaceutical compounding: a history, regulatory overview, and systematic review of compounding errors. J Med Toxicol. 2021;17:197\u2013217.","journal-title":"J Med Toxicol"},{"key":"3771_CR27","unstructured":"US Food & Drug Administration. Medications containing semaglutide marketed for type 2 diabetes or weight loss. 2024. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss#:~:text=Are%20there%20concerns%20with%20compounded,available%20to%20treat%20a%20patient. Accessed 24 May 2024."},{"key":"3771_CR28","unstructured":"US Food & Drug Administration. FDA Adverse Event Reporting System (FAERS) public dashboard. 2024. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard.\u00a0\u00a0Accessed 20 May 2024."},{"key":"3771_CR29","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","volume":"11","author":"A Vaisman-Mentesh","year":"2020","unstructured":"Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol. 2020;11:1951.","journal-title":"Front Immunol"},{"key":"3771_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fddsv.2022.952326","volume":"2","author":"AE Mattei","year":"2022","unstructured":"Mattei AE, Gutierrez AH, Martin WD, Terry FE, Roberts BJ, Rosenberg AS, De Groot AS. In silico immunogenicity assessment for sequences containing unnatural amino acids: a method using existing in silico algorithm infrastructure and a vision for future enhancements. Front Drug Discov (Lausanne). 2022;2: 952326.","journal-title":"Front Drug Discov (Lausanne)"},{"key":"3771_CR31","unstructured":"US Food & Drug Administration. Guidance for industry: immunogenicity assessment for therapeutic protein products. 2014. https:\/\/www.fda.gov\/media\/85017\/download. Accessed 11 August 2024."},{"key":"3771_CR32","unstructured":"United States Pharmacopeia. Plasma spectrochemistry 2022. 2022. https:\/\/www.biospectra.us\/images\/whitepapers\/elemental\/XXX_USP_General_Chapter_730.pdf. Accessed 11 August 2024."},{"key":"3771_CR33","unstructured":"United States Pharmacopeia. Chemical tests \/ <232> Elemental impurities \u2013 Limits. 2022. https:\/\/www.usp.org\/sites\/default\/files\/usp\/document\/our-work\/chemical-medicines\/key-issues\/c232-usp-39.pdf. Accessed 22 May 2024."},{"key":"3771_CR34","unstructured":"US Food & Drug Administration. Drug products or categories of drug products that present demonstrable difficulties for compounding under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. 2024. https:\/\/www.fda.gov\/media\/176946\/download?attachment. Accessed 20 May 2024."},{"key":"3771_CR35","doi-asserted-by":"publisher","first-page":"100071","DOI":"10.1016\/j.medidd.2020.100071","volume":"9","author":"MW Pennington","year":"2021","unstructured":"Pennington MW, Zell B, Bai CJ. Commercial manufacturing of current good manufacturing practice peptides spanning the gamut from neoantigen to commercial large-scale products. Med Drug Discov. 2021;9:100071.","journal-title":"Med Drug Discov"},{"key":"3771_CR36","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1021\/acs.oprd.3c00153","volume":"27","author":"RC Cioc","year":"2023","unstructured":"Cioc RC, Joyce C, Mayr M, Bream RN. Formation of N-nitrosamine drug substance related impurities in medicines: a regulatory perspective on risk factors and mitigation strategies. Org Process Res Dev. 2023;27:1736\u201350.","journal-title":"Org Process Res Dev"},{"key":"3771_CR37","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1002\/jssc.202200112","volume":"45","author":"K Suh","year":"2022","unstructured":"Suh K, Kyei I, Hage DS. Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: a review. J Sep Sci. 2022;45:2077\u201392.","journal-title":"J Sep Sci"},{"key":"3771_CR38","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.yrtph.2018.02.001","volume":"94","author":"JP Bercu","year":"2018","unstructured":"Bercu JP, Galloway SM, Parris P, Teasdale A, Masuda-Herrera M, Dobo K, et al. Potential impurities in drug substances: compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides. Regul Toxicol Pharmacol. 2018;94:172\u201382.","journal-title":"Regul Toxicol Pharmacol"},{"key":"3771_CR39","unstructured":"Novo Nordisk A\/S. US Patent for tablet formulation comprising semaglutide and a delivery agent patent (Patent # 9,993,430). 2013. https:\/\/patents.justia.com\/patent\/9993430. Accessed 17 Jun 2024."},{"key":"3771_CR40","unstructured":"US Food & Drug Administration. Final guidance for industry: safety risks associated with certain bulk drug substances nominated for use in compounding. 2023. https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/safety-risks-associated-certain-bulk-drug-substances-nominated-use-compounding. Accessed 18 Jul 2024."},{"key":"3771_CR41","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s40265-021-01499-w","volume":"81","author":"A Andersen","year":"2021","unstructured":"Andersen A, Knop FK, Vilsb\u00f8ll T. A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes. Drugs. 2021;81:1003\u201330.","journal-title":"Drugs"},{"key":"3771_CR42","doi-asserted-by":"publisher","first-page":"9936","DOI":"10.3390\/ijms22189936","volume":"22","author":"HS Kim","year":"2021","unstructured":"Kim HS, Jung CH. Oral semaglutide, the first ingestible glucagon-like peptide-1 receptor agonist: could it be a magic bullet for type 2 diabetes? Int J Mol Sci. 2021;22:9936.","journal-title":"Int J Mol Sci"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-024-03771-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-024-03771-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-024-03771-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T14:05:37Z","timestamp":1730469937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-024-03771-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["3771"],"URL":"https:\/\/doi.org\/10.1007\/s11095-024-03771-6","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees and shareholders of Novo Nordisk A\/S.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}